Elderly men over 65 years of age with late-onset hypogonadism benefit as much from test... - 0 views
www.ncbi.nlm.nih.gov/...PMC4392031
low T low Testosterone Testosterone men male hormone hormones late onset hypogonadism hypogonadism
![](/images/link.gif)
-
The benefits of restoring serum testosterone in men with LOH were not significantly different between men older than 65 years of age and younger men. There were no indications that side effects were more severe in elderly men. The effects on prostate and urinary function and hematocrit were within safe margins.
-
obesity, but also impaired general health, are the more common causes of low testosterone in aging men
- ...30 more annotations...
-
advanced age, obesity, a diagnosis of metabolic syndrome, and poor general health status were predictors of LOH
-
coronary heart disease, hypertension, stroke, and peripheral arterial disease did not predict hypogonadism, they did correlate with the incidence of low testosterone
-
LOH can be defined by the presence of at least three sexual symptoms associated with a total testosterone level of less than 11 nmol/L (3.2 ng/mL) and a free testosterone level of less than 220 pmol/L (64 pg/mL)
-
The benefits for men older than 65 years of age were compared with those of younger men, and the improvements in body weight, metabolic factors, psychological functioning, and sexual functioning were of the same magnitude in both age groups
-
weight loss was progressive over the 6-year period, effects of testosterone on lipids and on psychological and sexual functioning reached a plateau after approximately 3 years and these effects were sustained
-
Effects of testosterone on hematopoiesis, on the prostate, and on bladder function were not more severe in older men than in younger men
-
observe a mild increase in prostate volume and serum PSA over time, which is a normal finding in aging men. Maybe somewhat surprising, postvoiding residue and the IPSS did not deteriorate with aging but showed a degree of improvement
-
the severity of the metabolic syndrome is associated with the severity of lower urinary tract symptoms
-
The symptoms of the metabolic syndrome improve upon testosterone treatment and testosterone may thus have a favorable effect on lower urinary tract symptoms
-
it seems reasonable to conclude that the risks of testosterone administration to elderly men are not disproportionately higher in elderly men than in younger men.
-
Despite evidence to the contrary, physicians still harbor a wrongful association between testosterone and the development of prostate pathology (prostate cancer and benign prostate hyperplasia)
-
Not surprisingly, the incidence of prostate cancer was higher in older men; however, it was lower than expected in both groups
-
These observations suggest that the incidence of prostate cancer in patients receiving testosterone therapy, both in the younger and in the older group, was not greater than in the general population not receiving testosterone treatment
-
The historical fear that raising testosterone levels will result in more prostate cancer has been dispelled, particularly by the work of Abraham Morgentaler
-
Higher serum testosterone levels fail to show an increased risk of prostate cancer, and supraphysiological testosterone does not increase prostate volume or PSA in healthy men
-
Recent studies indicate no increased risk of prostate cancer among men with serum testosterone in the therapeutic range